Monotype India

Why is Monotype India Ltd falling/rising?

As of 08-Jun, Monotype India Ltd's stock price is rising at 0.40, with a 2.56% increase today, but it has been on a downward trend over the past week, month, and year. Despite the short-term rise, longer-term declines and reduced investor participation indicate ongoing challenges for the company.

As of 08-Jun, Monotype India Ltd's stock price is rising, currently at 0.40, reflecting a change of 0.01 or 2.56% increase. This rise is notable as the stock has outperformed its sector by 4.62% today. However, despite this positive movement, the stock has been experiencing a downward trend over the past week, month, and year, with declines of 4.76%, 16.67%, and 43.66% respectively. <BR><BR>Additionally, the stock is trading below its moving averages across various time frames, indicating a general bearish sentiment. The finance/NBFC sector has also seen a decline of 2.07%, which may influence investor sentiment. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by 36.03% compared to the 5-day average. <BR><BR>Overall, while there is a short-term rise in the stock price, the longer-term trends and declining investor participation suggest underlying challenges for Monotype India Ltd.

Which are the latest news on Monotype India?

Should I buy, sell or hold Monotype India Ltd?

When is the next results date for Monotype India Ltd?

The next results date for Monotype India Ltd is 28 May 2026.

The next results date for Monotype India Ltd is scheduled for 28 May 2026.

Are Monotype India Ltd latest results good or bad?

Monotype India Ltd's latest results are concerning, showing a net loss of ₹0.08 crores and zero revenue for Q1 and Q2 FY26, indicating a severe operational crisis. The company's financial health is alarming, with a significant decline in stock value and negative shareholder funds, suggesting a bleak outlook.

Monotype India Ltd's latest results are concerning and indicate a severe operational crisis. In Q2 FY26, the company reported a net loss of ₹0.08 crores, which is a significant deterioration compared to the previous year, with a decline of 102.68% year-over-year. Notably, the company generated zero revenue for both Q1 and Q2 FY26, marking a complete collapse in its business operations.<BR><BR>The operating margin has also plummeted to 0.00%, down from 12.71% in Q2 FY25, reflecting a total loss of profitability. Furthermore, the stock has seen a dramatic decline of 71.58% year-to-date, significantly underperforming the broader market.<BR><BR>The financial health of the company is alarming, with negative shareholder funds of ₹1.65 crores and a negative price-to-book ratio of -22.16, indicating that the market perceives it as a distressed asset. The rapid exit of promoters from their stakes, which dropped from 25.22% to 13.90% over the past year, adds to the negative sentiment surrounding the stock.<BR><BR>Overall, the results suggest that Monotype India is in a critical state, with no clear path to recovery, making the outlook for the company quite bleak.

How has been the historical performance of Monotype India?

Monotype India has shown significant recovery in financial performance, with net sales increasing from 4.58 Cr in Mar'24 to 61.97 Cr in Mar'25 and operating profit rising to 12.57 Cr. However, the company still faces challenges with negative total reserves of -71.96 Cr and fluctuating asset values.

Answer:<BR>The historical performance of Monotype India shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Monotype India's net sales have seen a notable increase from Mar'24 to Mar'25, rising from 4.58 Cr to 61.97 Cr, while the previous years showed varying results, including a peak of 210.34 Cr in Mar'18. The total operating income also reflects this trend, increasing to 61.97 Cr in Mar'25 from 4.58 Cr in Mar'24. Operating profit (PBDIT) has improved significantly, reaching 12.57 Cr in Mar'25 compared to 9.28 Cr in Mar'24, marking a recovery from previous losses. Profit before tax and profit after tax also showed positive growth, with figures of 12.57 Cr and 12.56 Cr respectively in Mar'25, indicating a strong turnaround from negative values in earlier years. However, the company continues to face challenges with total reserves remaining negative at -71.96 Cr in Mar'25, though this is an improvement from -84.52 Cr in Mar'24. The total liabilities decreased to 7.41 Cr in Mar'25 from 9.86 Cr in Mar'24, while total assets also declined to 7.41 Cr in Mar'25 from 9.86 Cr in Mar'24. Cash flow from operating activities was stable at 7.00 Cr in Mar'25, although cash flow from financing activities showed an outflow of -7.00 Cr. Overall, Monotype India has demonstrated a recovery in sales and profitability, but it still grapples with negative reserves and fluctuating asset values.

How big is Monotype India?

As of 24th July, Monotype India Ltd has a market capitalization of 49.00 Cr, with recent net sales of 59.30 Cr and a net profit of 10.29 Cr. The balance sheet for March 2024 shows shareholder's funds at -14.21 Cr and total assets at 9.86 Cr.

As of 24th July, Monotype India Ltd has a market capitalization of 49.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Monotype India reported Net Sales of 59.30 Cr and a Net Profit of 10.29 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds at -14.21 Cr and Total Assets at 9.86 Cr.

Is Monotype India overvalued or undervalued?

As of June 20, 2023, Monotype India is considered undervalued with a low PE ratio of 3.97 and an EV to EBITDA of 4.68, but it has moved to a "risky" classification due to a significant year-to-date decline of 61.75%, highlighting the need for caution despite its growth potential.

As of 20 June 2023, Monotype India has moved from a grade of "does not qualify" to "risky." The company is currently considered undervalued, primarily due to its low valuation ratios. Key ratios include a PE ratio of 3.97, an EV to EBITDA of 4.68, and a PEG ratio of 0.11, indicating significant potential for growth relative to its price.<BR><BR>In comparison to its peers, Monotype India stands out with a much lower PE ratio than Life Insurance at 12.54 and Bajaj Finance at 35.01, both of which are categorized as fairly valued and very expensive, respectively. The company's return metrics have been concerning, with a year-to-date decline of 61.75% compared to a 5.62% increase in the Sensex, highlighting the volatility and risk associated with the stock. Overall, while Monotype India is undervalued based on its ratios, the risks associated with its current valuation and performance should be carefully considered.

What is the technical trend for Monotype India?

As of May 12, 2025, Monotype India shows a mildly bearish technical trend, with bearish Bollinger Bands and moving averages, despite some mixed signals from the MACD and KST.

As of 12 May 2025, the technical trend for Monotype India has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are also bearish. The KST shows a mildly bullish stance weekly but is mildly bearish monthly. There are no clear trends indicated by Dow Theory on either time frame. Overall, the current technical stance is mildly bearish, driven primarily by the bearish Bollinger Bands and moving averages, despite some mildly bullish signals from the MACD and KST on the weekly chart.

Who are the top shareholders of the Monotype India?

The top shareholders of Monotype India are Sandeep Ispat Trader LLP with 10.8%, Vedant Commodeal Private Limited at 3.91%, and individual investors holding 67.1%. There are no pledged promoter holdings, and the company has no mutual fund or foreign institutional investor involvement.

The top shareholders of Monotype India include Sandeep Ispat Trader LLP, which holds the highest promoter stake at 10.8%. The highest public shareholder is Vedant Commodeal Private Limited, with a holding of 3.91%. Additionally, individual investors collectively hold a significant portion of 67.1%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) involvement.

What does Monotype India do?

Monotype India Ltd is a micro-cap company engaged in trading shares and providing financial services, with net sales of 14 Cr and a net profit of 7 Cr as of March 2025. It was incorporated in 1974 and is based in Mumbai.

Overview: <BR>Monotype India Ltd is engaged in trading in shares, financial services, and investment activities within the diversified commercial services industry, categorized as a micro-cap company.<BR><BR>History: <BR>Monotype India Ltd was incorporated on 30th September 1974 in Calcutta and converted into a public limited company on 23rd October 1976. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 14 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 7 Cr (Quarterly Results - Mar 2025) <BR>- Market-cap: Rs 50 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 4.00 <BR>- Industry P/E: 23 <BR>- Dividend Yield: 0.00% <BR>- Debt-Equity: -5.35 <BR>- Return on Equity: -761.21% <BR>- Price to Book: -30.68 <BR><BR>Contact Details: <BR>Address: 602 6 Th floor Raheja Chambers, 213 Nariman Point Mumbai Maharashtra : 400001 <BR>Tel: 022-40068190/91 <BR>Email: monotypeindialtd@gmail.com <BR>Website: http://www.monotypeindia.in

Who are in the management team of Monotype India?

As of March 2019, the management team of Monotype India includes Naresh Manakchand Jain (Whole-time Director), Suryakant Maruti Kadakane (Independent Director), Preeti Doshi (Independent Director), and Rajendra Redekar (Director and Additional Independent Director). They are responsible for the company's strategic direction and governance.

As of March 2019, the management team of Monotype India includes the following individuals:<BR><BR>1. Naresh Manakchand Jain - Whole-time Director<BR>2. Suryakant Maruti Kadakane - Independent Director<BR>3. Preeti Doshi - Independent Director<BR>4. Rajendra Redekar - Director<BR>5. Rajendra Redekar - Additional Independent Director<BR><BR>These members play various roles in guiding the company's strategic direction and governance.

Has Monotype India declared dividend?

No Dividend History Available

Who are the peers of the Monotype India?

Monotype India's peers include International Ge, CMS Info Systems, NESCO, SIS, Nirlon, Johnson Pharma, Rithwik Facility, Satchmo Holdings, and Enbee Trade. Key metrics show varying management risks, growth rates, and capital structures, with Nirlon having the highest 1-year return at 22.15% and Monotype India at -27.45%.

Peers: The peers of Monotype India are International Ge, CMS Info Systems, NESCO, SIS, Nirlon, Johnson Pharma, Rithwik Facility, Satchmo Holdings, Enbee Trade.<BR><BR>Quality Snapshot: Excellent management risk is observed at International Ge, while Good management risk is found at CMS Info Systems and Nirlon. Average management risk is present at NESCO and SIS, and Below Average management risk is noted for Johnson Pharma, Rithwik Facility, and Enbee Trade. The peers with Below Average growth include CMS Info Systems, NESCO, SIS, Rithwik Facility, and Johnson Pharma, while Average growth is seen at Nirlon. Enbee Trade exhibits Excellent growth, and Monotype India does not qualify. Excellent capital structure is noted at International Ge, CMS Info Systems, NESCO, and Enbee Trade, while Good capital structure is observed at SIS and Johnson Pharma. Below Average capital structure is found at Nirlon, and Monotype India does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Nirlon at 22.15%, while Johnson Pharma has the lowest at -12.75%. Monotype India's 1-year return is -27.45%, which is lower than both. Additionally, SIS, NESCO, Johnson Pharma, Satchmo Holdings, and Enbee Trade all have negative six-month returns.